Proposed appointment of independent non-executive director; and (2) notice of 2026 first extraordinary general meeting
Filed with HKEX · Stock code 2185 · · 13 pages · English
If you are in any doubt about this circular or as to the action to be taken, you should consult your stockbroker, or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser. If you have sold or transferred all your shares in Shanghai Bio-heart Biological Technology Co., Ltd., you should at once hand this circular with the enclosed form
Shanghai Bio-Heart Biological Technology Co., Ltd. on 6ix
Earlier from Shanghai Bio-Heart Biological Technology
- Notice of 2026 first extraordinary general meeting
- Announcement pursuant to rule 13.51B(2) of the listing rules
- Voluntary announcement strategic cooperation agreement with shanghai shenqi medical technology co., ltd. to advance the commercialisation of the bioheart bioabsorbable rapamycin-eluting coronary stent system
- Articles of association
Later from Shanghai Bio-Heart Biological Technology
- Proxy form for use at the 2026 first extraordinary general meeting to be held on October 9, 2026
- 2026 Interim report
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
- (1) Poll results of the 2026 first extraordinary general meeting held on October 9, 2026; (2) resignation of independent non-executive director; (3) appointment of independent non-executive director; and (4) change of composition of board committees
- List of directors and their roles and functions
Follow Shanghai Bio-Heart Biological Technology into a list and get an email when it puts out news.
Follow Shanghai Bio-Heart Biological Technology